SCHEMBL4502200

SCHEMBL4502200

[NH]C(=S)Nc1cccc2cc[nH]c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 1/20 0.49
▸ PGR P06401 1/20 0.49
▸ NR3C2 P08235 1/20 0.49
▸ AR P10275 1/20 0.49
▸ AHR P35869 1/20 0.43
▸ TRPV1 Q8NER1 1/20 0.42
▸ KEAP1 Q14145 1/20 0.42
▸ PDPK1 O15530 1/20 0.41
▸ GLA P06280 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ BACE1 P56817 1/20 0.40
▸ ATR Q13535 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ BCHE P06276 3/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ GRM5 P41594 1/20 0.38
▸ EGFR P00533 1/20 0.36
▸ PTPRC P08575 1/20 0.36
▸ PTPN2 P17706 1/20 0.36
▸ PTPN1 P18031 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4502201 0.83 L3MBTL1 (0.58) NR3C1PGRNR3C2ARAHR
SCHEMBL31668677 0.80 MAOB (0.51) NR3C1PGRNR3C2ARTRPV1
SCHEMBL27698981 0.77 KEAP1 (0.56) NR3C1PGRNR3C2ARAHR
SCHEMBL31456523 0.76 NR3C1 (0.57) NR3C1PGRNR3C2ARTRPV1
SCHEMBL30026274 0.76 PDPK1 (0.57) NR3C1PGRNR3C2ARAHR
SCHEMBL6091339 0.76 NR3C1 (0.57) NR3C1PGRNR3C2ARTRPV1
SCHEMBL5497010 0.76 PDPK1 (0.57) NR3C1PGRNR3C2ARAHR
SCHEMBL25581593 0.73 NR3C1 (0.54) NR3C1PGRNR3C2ARAHR
SCHEMBL31668711 0.73 TRPV1 (0.65) NR3C1PGRNR3C2ARTRPV1
SCHEMBL4511260 0.72 MAPK1 (0.71) AHRTRPV1MAPK1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233960-A1 Kinase Inhibitors DEVGEN NV (BE) 2009-09-17 — — US disclosed
EP-1934181-A2 KINASE INHIBITORS Devgen NV (BE) 2008-06-25 — — EP disclosed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233960-A1 Kinase Inhibitors ROCK1, MAP3K1, MAP3K11 NR3C1 746/4885PGR 1068/4885NR3C2 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback